Shanghai Rongtai Health Technology Corporation (603579) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 3.9B CNY
Analysis
Shanghai Rongtai Health Technology Corporation (603579) currently trades at ¥19.42, while our model-based Fair Value estimate is ¥9.39 — implying the stock looks roughly 51.6% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Shanghai Rongtai Health Technology Corporation Limited, together with its subsidiaries, engages in the research, design, development, production, and sale of massage equipment under the Rongtai and Momoda brands in China and internationally. The company offers massage chairs and accessories, neck massagers, eye massagers, massage backrests, massage belts, foot massagers, massage pads, and handheld massagers, etc.; ankle revive, ROVO walking, small massagers, and other products; and smart home health gadgets, including slimming machines and beauty devices. It also provides shared massage services, as well as purchase and after-sale services. The company sells its products through direct sales, e-commerce, sales counters in department stores, and distributors. It exports its products. The company is also involved in the software and financial; import and export of goods and technologies; technology promotion and application; investing; and wholesale and retail trade activities. Shangh…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.